Patients with CRC having copy number amplification and expressing higher EPAS1 mRNA had better survival time (4 and 5 months, respectively) when compared to those with EPAS1 copy number deletion and lower mRNA expression. This evidence concerns the gene EPAS1 and colorectal carcinoma.